🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the battle against drug-resistant strains of the bacteria, according to researchers.

A Global Challenge

Cases of gonorrhoea are increasing globally, with estimates suggesting over 82 million new cases per year. Particularly high rates are observed in the African continent and nations within the WHO's designated area, which includes Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an important and timely step in the context of rising global incidence, escalating drug resistance and the extremely scarce therapeutic options at this time.”

Public health authorities are increasingly worried about the increase in antibiotic-resistant strains. The World Health Organization has classified it as a "critical concern". A tracking program revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Gain Approval

One new antibiotic, alternatively called a brand name, was approved by the American regulatory agency in mid-December for combating gonorrhoea. This disease can lead to major issues, including infertility. Experts anticipate that focused deployment of this new drug will help delay the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This medication, which is additionally indicated for urinary tract infections, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to develop it.

“This authorization marks a huge turning point in the therapy of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Testing Results and Worldwide Availability

As per results released by a prominent scientific publication, zoliflodacin cured more than 90% of uncomplicated infections. This places it at an comparable level with the existing first-line therapy, which involves a dual-drug approach. The research enrolled hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the rights to register and commercialise the drug in many low-income and middle-income countries.

Clinicians on the front lines have voiced optimism. Access to a single-dose, oral treatment like this is seen as a "critical tool" for public health efforts. This is deemed essential to alleviate the strain of the disease for patients and to stop the proliferation of highly drug-resistant gonorrhoea globally.